NCT05165394 - Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

July 7, 2023

Study Completion Date

September 13, 2023

Conditions

AnhedoniaMajor Depressive Disorder

Interventions

DRUG

Placebo

Tablets for oral administration

DRUG

NBI-1065846

Tablets for oral administration

Trial Locations (23)

27609

Neurocrine Clinical Site, Raleigh

30338

Neurocrine Clinical Site, Atlanta

32502

Neurocrine Clinical Site, Pensacola

32792

Neurocrine Clinical Site, Winter Park

32803

Neurocrine Clinical Site, Orlando

35294

Neurocrine Clinical Site, Birmingham

43210

Neurocrine Clinical Site, Columbus

60076

Neurocrine Clinical Site, Skokie

60641

Neurocrine Clinical Site, Chicago

63304

Neurocrine Clinical Site, Saint Charles

73112

Neurocrine Clinical Site, Oklahoma City

75235

Neurocrine Clinical Site, Dallas

77030

Neurocrine Clinical Site, Houston

77546

Neurocrine Clinical Site, Friendswood

84107

Neurocrine Clinical Site, Murray

91945

Neurocrine Clinical Site, Lemon Grove

92103

Neurocrine Clinical Site, San Diego

92506

Neurocrine Clinical Site, Riverside

92845

Neurocrine Clinical Site, Garden Grove

92868

Neurocrine Clinical Site, Orange

94107

Neurocrine Clinical Site, San Francisco

98201

Neurocrine Clinical Site, Everett

00926

Neurocrine Clinical Site, San Juan